Nuveen Asset Management LLC Sells 112,307 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Nuveen Asset Management LLC trimmed its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 54.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,665 shares of the company's stock after selling 112,307 shares during the period. Nuveen Asset Management LLC owned about 0.20% of Amphastar Pharmaceuticals worth $3,552,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. Smartleaf Asset Management LLC raised its stake in Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after acquiring an additional 493 shares during the period. Parkside Financial Bank & Trust raised its stake in Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock valued at $36,000 after acquiring an additional 871 shares during the period. Tower Research Capital LLC TRC raised its stake in Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after acquiring an additional 348 shares during the period. Huntington National Bank raised its stake in Amphastar Pharmaceuticals by 36.9% in the 4th quarter. Huntington National Bank now owns 1,340 shares of the company's stock valued at $50,000 after acquiring an additional 361 shares during the period. Finally, TD Private Client Wealth LLC grew its holdings in Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock valued at $78,000 after buying an additional 388 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on AMPH shares. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Wells Fargo & Company reduced their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $32.33.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH traded down $0.34 during midday trading on Thursday, hitting $25.52. 555,155 shares of the company's stock were exchanged, compared to its average volume of 485,447. Amphastar Pharmaceuticals, Inc. has a 12-month low of $22.64 and a 12-month high of $53.96. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The company has a market cap of $1.20 billion, a price-to-earnings ratio of 8.51, a PEG ratio of 2.19 and a beta of 0.78. The business's fifty day moving average price is $24.68 and its two-hundred day moving average price is $31.71.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.